2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.32 Sun

PP01.32 Sun - Poster

Pdf Summary

The document discusses the impact of de novo co-mutations on clinical outcomes in patients with EGFR-mutated non-small cell lung cancer (NSCLC) receiving first-line osimertinib treatment. EGFR mutations are found in a subset of NSCLC patients, and osimertinib is a targeted therapy used as a first-line treatment. The study aims to characterize the frequency of co-mutations and their impact on treatment failure and overall survival. The research examines genes such as TP53, KRAS, and PIK3CA, and their relationship with response to osimertinib. The results show that patients with fewer co-mutations had longer overall survival compared to those with more co-mutations. Co-occurring alterations in genes involved in epigenetic modification were associated with shorter survival times. The study highlights the importance of identifying high-risk patients to personalize treatment strategies. The data was collected through a single-institution retrospective cohort study using next-generation sequencing assays. Future directions include expanding the study across multiple institutions to gather more comprehensive data. The findings suggest that baseline tumor genomic complexity and specific genetic alterations may play a role in predicting clinical outcomes in patients receiving osimertinib. The document also provides information on patient demographics, treatment responses, and reasons for treatment discontinuation in the study population. Further research in this area can potentially improve prognostic assessments and treatment approaches for EGFR-mutated NSCLC patients.

Keywords

EGFR-mutated non-small cell lung cancer

osimertinib treatment

co-mutations

clinical outcomes

TP53

KRAS

PIK3CA

epigenetic modification

next-generation sequencing assays

tumor genomic complexity